In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Ogeda S.A.

Astellas’s Long-Term Safety Data Could Boost Fezolinetant’s Approval Chances

With a pair of successful Phase III pivotal studies in hand, the Japanese pharma reports that its nonhormonal hot flash/night sweats candidate demonstrated safety and tolerability over 52 weeks.

Clinical Trials Drug Safety

True Innovation In Women’s Health Hindered Because Conditions Are Not Fatal

Drug developers and financiers discuss the biggest challenges delaying novel R&D in diseases effecting only women and how poor awareness of the debilitating symptoms that come with some conditions has led to a lack of emphasis on innovative research.

Clinical Trials Innovation

Menopausal Symptoms Cooled By KaNDy's Dual Neurokinin Antagonist

Faster relief of debilitating menopausal symptoms in early-stage clinical trial results suggest a potential new class of products being evaluated by UK biotech KaNDy Therapeutics may be useful against the condition.

Clinical Trials Metabolic Disorders

Takeda Paves The Way For Myovant With Phase III Fibroid Success

Takeda has reported the first in a wave of Phase III trials to support the potential uterine fibroid therapy relugolix. The news is good for licensee Myovant, which earlier this year started two larger Phase III studies of the product.

Clinical Trials Companies
See All

Company Information

  • Other Names / Subsidiaries
    • Euroscreen
UsernamePublicRestriction

Register